Zobrazeno 1 - 10
of 825
pro vyhledávání: '"Wu Zhuang"'
Autor:
Yaping Hong, Wu Zhuang, Jinhuo Lai, Haipeng Xu, Yueming He, Jinlan Lin, Qin Shi, Shengjia Chen, Zhangzhou Huang, Shijie Chen, Dongzhu Lu, Gen Lin, Yunjian Huang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Plasma epidermal growth factor receptor mutation (EGFRm) circulating tumor DNA (ctDNA) dynamics exhibit promise in predicting outcomes in patients with EGFRm-advanced non-small cell lung cancer (NSCLC). However, there remains limited trial-l
Externí odkaz:
https://doaj.org/article/15d99de768db44beba5ec8321e298a39
Autor:
Jing Zheng, Tao Wang, Yunpeng Yang, Jie Huang, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Giovanni Selvaggi, Yang Wang, Shanshan Xiao, Qian Wang, Zhilin Shen, Jianya Zhou, Jianying Zhou, Li Zhang
Publikováno v:
Cancer Communications, Vol 44, Iss 4, Pp 455-468 (2024)
Abstract Background The initial phase II stuty (NCT03215693) demonstrated that ensartinib has shown clinical activity in patients with advanced crizotinib‐refractory, anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC).
Externí odkaz:
https://doaj.org/article/dcd1b31af767472781f48f4856ca4755
Autor:
Jing Gao, Yan Song, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Xiao Qi, Qingyu Wang, Jun Zhu, Jing Huang
Publikováno v:
Cancer Medicine, Vol 13, Iss 10, Pp n/a-n/a (2024)
Abstract Objective To explore the efficacy of serplulimab plus chemotherapy in esophageal squamous cell carcinoma (ESCC) patients with liver metastases. Methods A post hoc exploratory analysis of ASTRUM‐007 study was performed, focusing on the asso
Externí odkaz:
https://doaj.org/article/853c821061684aecbd227cf8265e2157
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Small-cell lung cancer (SCLC) is a highly aggressive and lethal malignancy that accounts for 10–15% of lung cancers, and it is generally divided into limited and extensive stage. The standard of care for patients with newly diag
Externí odkaz:
https://doaj.org/article/df75f7cce631475bba33d7db0adcd075
Autor:
Yunpeng Yang, Jie Min, Nong Yang, Qitao Yu, Ying Cheng, Yanqiu Zhao, Manxiang Li, Hong Chen, Shou’an Ren, Jianying Zhou, Wu Zhuang, Xintian Qin, Lejie Cao, Yan Yu, Jian Zhang, Jianxing He, Jifeng Feng, Hao Yu, Li Zhang, Wenfeng Fang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-8 (2023)
Abstract Anaplastic lymphoma kinase (ALK) rearrangements are present in about 5–6% of non-small cell lung cancer (NSCLC) cases and associated with increased risks of central nervous system (CNS) involvement. Envonalkib, a novel ALK inhibitor, demon
Externí odkaz:
https://doaj.org/article/2147bdf7a75e4cf189fd4a0c98e7ad89
Autor:
Shun Lu, Hongming Pan, Lin Wu, Yu Yao, Jianxing He, Yan Wang, Xiuwen Wang, Yong Fang, Zhen Zhou, Xicheng Wang, Xiuyu Cai, Yan Yu, Zhiyong Ma, Xuhong Min, Zhixiong Yang, Lejie Cao, Huaping Yang, Yongqian Shu, Wu Zhuang, Shundong Cang, Jian Fang, Kai Li, Zhuang Yu, Jiuwei Cui, Yang Zhang, Man Li, Xinxuan Wen, Jie Zhang, Weidong Li, Jianhua Shi, Xingxiang Xu, Diansheng Zhong, Tao Wang, Jiajia Zhu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-11 (2023)
Abstract This phase I/II trial characterized the tolerability, safety, and antitumor activities of unecritinib, a novel derivative of crizotinib and a multi-tyrosine kinase inhibitor targeting ROS1, ALK, and c-MET, in advanced tumors and ROS1 inhibit
Externí odkaz:
https://doaj.org/article/abb77573f5db4043b5967b91a2aae0b2
Autor:
Shen Zhao, Wu Zhuang, Baohui Han, Zhengbo Song, Wei Guo, Feng Luo, Lin Wu, Yi Hu, Huijuan Wang, Xiaorong Dong, Da Jiang, Mingxia Wang, Liyun Miao, Qian Wang, Junping Zhang, Zhenming Fu, Yihua Huang, Chunwei Xu, Longyu Hu, Lei Li, Rong Hu, Yang Yang, Mengke Li, Xiugao Yang, Li Zhang, Yan Huang, Wenfeng Fang
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Abstract EGFR exon 20 insertion (20ins)-positive non-small-cell lung cancer (NSCLC) is an uncommon disease with limited therapeutic options and dismal prognosis. Here we report the activity, tolerability, potential mechanisms of response and resistan
Externí odkaz:
https://doaj.org/article/845e14a04dc6483197124325ef24177b
Autor:
Yuanyuan Zhao, Gang Chen, Jianhua Chen, Li Zhuang, Yingying Du, Qitao Yu, Wu Zhuang, Yanqiu Zhao, Ming Zhou, Weidong Zhang, Yu Zhang, Yixin Wan, Wenting Li, Weifeng Song, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang
Publikováno v:
EClinicalMedicine, Vol 62, Iss , Pp 102106- (2023)
Summary: Background: Inhibiting vascular endothelial growth factor (VEGF) function can improve the efficacy of immunotherapy by modulating the tumor immune microenvironment. AK112 is the first-in-class humanized IgG1 bispecific antibody targeting pro
Externí odkaz:
https://doaj.org/article/6e8da08ef1ff476985a5ce74f12c55cf
Autor:
Guangrun Zhou, Jifang Zheng, Zhiwei Chen, Dan Hu, Suyu Li, Wu Zhuang, Zhiyong He, Gen Lin, Biao Wu, Wei Zhang, Weimin Fang, Fei Zheng, Jiezhong Wang, Gang Chen, Mingqiu Chen
Publikováno v:
Radiation Oncology, Vol 17, Iss 1, Pp 1-12 (2022)
Abstract Background Tumor-infiltrating lymphocytes (TILs), investigated using routine hematoxylin and eosin (H&E)-stained section slides (H&E-sTILs), provide a robust prognostic biomarker in various types of solid cancer. The purpose of the present s
Externí odkaz:
https://doaj.org/article/a2f8037c436d4ada9fe03b7cf87f4372
Publikováno v:
Thoracic Cancer, Vol 13, Iss 5, Pp 750-760 (2022)
Abstract Background The development of non‐small cell lung cancer (NSCLC) is associated with the deregulation of circRNAs. The objective of this study was to investigate the effects of circ‐RAD23B in NSCLC. Methods Circ‐RAD23B expression, miR
Externí odkaz:
https://doaj.org/article/6a2a4b1f61354333ac377211450aa940